A61P 19 - Drugs for skeletal disorders

Patents for A61P 19 - Drugs for skeletal disorders (81,981)
11/2002
11/20/2002	CN1380087A Compound kidney-tonifying and bone-strengthening mixture
11/20/2002	CN1094354C Nafiverine injection
11/19/2002	US6482852 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof
11/19/2002	US6482848 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
11/19/2002	US6482834 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
11/19/2002	US6482830 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
11/19/2002	US6482825 Growth-hormone secretagogues
11/19/2002	US6482822 N-(iminomethyl)amines derivatives, their preparation, their use as medicines and compositions containing them
11/19/2002	US6482813 Steroids substituted at the 11-position, process for their preparation, their use as medicament and the pharmaceutical compositions containing them
11/19/2002	US6482812 Method of locking 1α-OH of vitamin D compounds in axial orientation
11/19/2002	US6482809 Use of tiludronic acid and derivatives thereof in poultry for the preparation of a medicinal product for preventing and treating osteoporosis
11/19/2002	US6482411 Osteoporosis
11/14/2002	WO2002090600A2 A method for regulating immune function in primates using the foxp3 protein
11/14/2002	WO2002090530A2 Kinases and phosphatases
11/14/2002	WO2002090524A2 Isolated nucleic acid molecules encoding a novel human signal transducing kinase-mapkap-2; encoded proteins, cells transformed therewith and uses thereof
11/14/2002	WO2002090355A1 N-aroyl cyclic amines
11/14/2002	WO2002090353A1 Sulfonamides
11/14/2002	WO2002090349A1 N-oxide anthranylamide derivatives and their use as medicaments
11/14/2002	WO2002090348A1 Sulfonamides
11/14/2002	WO2002090346A1 Phthalazine derivatives with angiogenesis inhibiting activity
11/14/2002	WO2002090337A1 Sulfonamides
11/14/2002	WO2002090332A2 Novel aeylheteroalkylaminε derivatives
11/14/2002	WO2002090330A1 Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives
11/14/2002	WO2002090326A1 Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists
11/14/2002	WO2002090325A2 Benzazepinone alpha v integrin receptor antagonists
11/14/2002	WO2002090317A1 Substituted cyclohexane-1,4-diamine derivatives
11/14/2002	WO2002089816A1 Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis
11/14/2002	WO2002089800A2 N-aroyl cyclic amine derivatives as orexin receptor antagonists
11/14/2002	WO2002089793A1 Sulfonamides
11/14/2002	WO2002089792A1 Sulfonamides
11/14/2002	WO2002089787A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	WO2002089785A1 Sulfonamides
11/14/2002	WO2002089783A1 Substituted cyclohexan-1,4-diamine derivatives with constipating and peripheral analgesic properties
11/14/2002	WO2002089768A1 Liquid injectable formulation of disodium pamidronate
11/14/2002	WO2002089749A2 Arylsulfonamide ethers, and methods of use thereof
11/14/2002	WO2002089740A2 Sulfonamides
11/14/2002	WO2002076476A3 Prodrugs of anticancer agents employing substituted aromatic acids
11/14/2002	WO2002072577A3 Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors.
11/14/2002	WO2002066051A8 Use of the g-csf as adjuvant treatment in connective tissue recontruction
11/14/2002	WO2002066028A3 Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids
11/14/2002	WO2002064550A8 Glucocorticoid receptor modulators
11/14/2002	WO2002018623A3 Methods and reagents for protease inhibition
11/14/2002	WO2002011530A9 Transgenic animal
11/14/2002	US20020169336 Able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders
11/14/2002	US20020169314 Sulfonamide derivative as a matrix metalloproteinase inhibitor
11/14/2002	US20020169215 Treatment of a disease that is mediated by the expression or suppression of a redox sensitive gene, for example MCP-1, IL-6 and thrombin receptor; antiinflammatory agents; cardio-vascular disorders; atherosclerosis; immunology
11/14/2002	US20020169210 Method for treating or preventing bone fracture
11/14/2002	US20020169209 Potentiation of therapeutic effects of fatty acids
11/14/2002	US20020169200 Antitumor, antiinflammatory and antiarthritic agents, treating metastasis, restenosis, osteoporosis, inflammation, macular degeneration, and diabetic retinopathy
11/14/2002	US20020169177 Imidazole and benzimidazole caspase inhibitors and uses thereof
11/14/2002	US20020169164 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
11/14/2002	US20020169162 Device and method for treating conditions of a joint
11/14/2002	US20020169160 Sulfonamide matrix metalloproteinase inhibitors
11/14/2002	US20020169159 An acetamide derivative is useful for treatment of inflammatory and immune conditions and diseases; modulates the expressin and/or function of a chemokine receptor
11/14/2002	US20020169150 Hormone replacement therapy
11/14/2002	US20020169144 Angiogenesis inhibition
11/14/2002	US20020169133 Treatment of diseases characterized by excessive deposits of fibrillar interstitial collagens that are resistant to proteolyic degradation thus leading to symptoms of fibrosis
11/14/2002	US20020169131 TGF-alpha polypeptides, functional fragments and methods of use therefor
11/14/2002	US20020169122 Chondrogenic potential of human bone marrow-derived CD105+ cells by BMP
11/14/2002	US20020168763 Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same
11/14/2002	US20020168716 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of tumors, immunological, autoimmune, skin, viral, bone, nervous system and inflammatory disorders
11/14/2002	US20020168435 Composition for promoting regeneration of hard tissues comprising an extract of cortex eucommiae
11/14/2002	US20020168434 Cyclooxygenase inhibitor; anticancer agents, Alzheimer's disease, central nervous system disorders
11/14/2002	US20020168433 Plant extracts; mixture of isoflavones, lignan, saponin, catechin and benzoic acid
11/14/2002	US20020168363 Integrin/adhesion antagonists
11/14/2002	US20020168360 Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphanubeta3 antagonists in combination with other prophylactic or therapeutic agents
11/14/2002	US20020168358 Modulating the binding of the particular chemokines SLC (secondary lymphoid chemokine), and MIP-3b (macrophage inflammatory protein-3b), to immune system T-cells and dendritic cells to treat adverse inflammatory responses etc
11/14/2002	DE10123129A1 Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel Deuterated 3-piperidinopropiophenones and pharmaceutical compositions containing them
11/14/2002	DE10119680A1 Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation Use of scavenger compounds for the treatment and prevention of no-dependent disorders of microcirculation
11/14/2002	CA2446735A1 Substituted cyclohexane-1,4-diamine derivatives with an anti-diarrhoea and peripheral analgesic action
11/14/2002	CA2446396A1 N-aroyl cyclic amines
11/14/2002	CA2446365A1 Sulfonamides
11/14/2002	CA2446363A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	CA2446120A1 Novel arylheteroalkylamine derivatives
11/14/2002	CA2446051A1 Phthalazine derivatives with angiogenesis inhibiting activity
11/14/2002	CA2445923A1 Arylsulfonamide ethers, and methods of use thereof
11/14/2002	CA2445679A1 Benzazepinone alpha v integrin receptor antagonists
11/14/2002	CA2444718A1 Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis
11/14/2002	CA2438978A1 Isolated nucleic acid molecules encoding a novel human signal transducing kinase-mapkap-2; encoded proteins, cells transformed therewith and uses thereof
11/14/2002	CA2435142A1 Kinases and phosphatases
11/13/2002	EP1256344A1 Remedies for endothelin-induced diseases
11/13/2002	EP1255844A1 Humanized anti-ccr2 antibodies and methods of use therefor
11/13/2002	EP1255764A1 Purine derivatives
11/13/2002	EP1255760A1 Clavams as protease inhibitors
11/13/2002	EP1255756A1 Saccharin derivatives as orally active elastase inhibitors
11/13/2002	EP1255752A2 Pyrrole substituted 2-indolinone protein kinase inhibitors
11/13/2002	EP1255744A1 Substituted phenylamidines medicaments containing said compounds and method for production thereof
11/13/2002	EP1255740A2 Substituted arylpyrazines
11/13/2002	EP1255732A1 Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives
11/13/2002	EP1255726A2 (r)-2-aryl-propionamides, useful in the inhibition of il-8 induced chemiotaxis of neutrophils
11/13/2002	EP1255546A1 Method for improving bone modeling and chondrocyte functioning in growing canines
11/13/2002	EP1255542A1 Substituted amino acids as neutral sphingomyelinase inhibitors
11/13/2002	EP1255536A2 Indolinone derivatives for modulation of c-kit tyrosine protein kinase
11/13/2002	EP1140916B1 Heteroaryl-cyclic acetals
11/13/2002	EP0952851A4 Anti-carious chewing gums, candies, gels, toothpastes and dentifrices
11/13/2002	EP0760658B1 Compounds for inhibiting osteoclast-mediated bone resorption
11/13/2002	EP0748320B1 Prodrugs of morpholine tachykinin receptor antagonists
11/13/2002	CN1379816A Human G-protein coupled receptor
11/13/2002	CN1379786A Modified peptides and peptidomimetics for use in immunotherapy
11/13/2002	CN1379785A Caspase inhibitors for treatment and prevention of chemotherapy and radiation therapy induced cell death

1 ... 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 ... 820